Related Experiment Videos
Central precocious puberty. An overview of diagnosis, treatment, and outcome
1Department of Pediatrics, University of Pittsburgh School of Medicine, Pennsylvania, USA.
Insights
Central precocious puberty (CPP) is early-onset puberty driven by elevated gonadotropin-releasing hormone (GnRH). GnRH analogue therapy effectively halts pubertal progression, preventing compromised adult height.
Area of Science:
- Pediatric endocrinology
- Reproductive medicine
Background:
- Central precocious puberty (CPP) involves early onset of normal puberty.
- It results from premature stimulation of the hypothalamic-pituitary-gonadal axis.
- This leads to accelerated growth and development.
Purpose of the Study:
- To define Central Precocious Puberty (CPP).
- To outline diagnostic methods for CPP.
- To evaluate the efficacy of Gonadotropin-Releasing Hormone (GnRH) analogue therapy in managing CPP.
Main Methods:
- GnRH stimulation testing is the gold standard for diagnosing CPP.
- Treatment involves GnRH analogue therapy for progressive cases.
- Monitoring pubertal progression and growth rate.
Main Results:
- GnRH stimulation tests confirm CPP through pubertal gonadotropin responses.
- GnRH analogue therapy effectively reduces gonadotropin secretion.
- This therapy halts pubertal progression and improves adult height outcomes.
Conclusions:
- CPP is characterized by early puberty due to increased GnRH regulation.
- GnRH stimulation testing is definitive for diagnosis.
- GnRH analogue therapy is a safe and effective treatment for progressive CPP, preventing adverse growth outcomes.
Abstract:
Central precocious puberty (CPP) is physiologically normal puberty beginning early. It is the consequence of early increased regulation of gonadotropin releasing hormone (GnRH) stimulation of pituitary gonadotropin release causing pubertal changes and accelerated growth. GnRH stimulation testing is the definitive diagnostic test--pubertal gonadotropin responses being indicative of CPP. Among patients with progressive CPP, GnRH analogue therapy is effective by decreased regulation of gonadotropin secretion. Pubertal progression is stopped, and accelerated growth rate and compromised adult height are precluded or alleviated. Outcome data have not identified unusual sequelae.